Clinical Trials

Our Ongoing Clinical Trials

Syndax is developing entinostat, axatilimab (SNDX-6352), and SNDX-5613 in multiple indications.
Note that trials currently recruiting appear first.
See below for further details, or contact us at [email protected] or 1-833-636-4648.

Currently Recruiting


Recruiting
SNDX-5613-0700/AUGMENT-101
NCT04065399
A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101).

Recruiting
SNDX-6352-0503
NCT03604692
A Phase 1, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, PK and PD Activity of axatilimab (SNDX-6352) in Subjects With Active cGVHD Who Have Received at Least 2 Lines of Prior Therapy.